CRP and cancer: Further analysis indicated that 1 mg/dl was appropriate as a cutoff value for determining the low or high level of baseline CRP to predict the OS or PFS of cancer patients receiving ICI treatment (univariate analysis: HR = 1.56, 95% CI = 1.24-1.97, <i>P</i> = 0.909; multivariate analysis: HR = 1.58, 95% CI = 1.23-2.03, <i>P</i> = 0.521).<h4>Conclusions</h4>High baseline CRP level (>1 mg/dl) may be an indicator for worse OS and PFS of cancer patients treated with ICIs.